Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
congress
4
×
detroit blog main
detroit top stories
life sciences
national
4
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
indiana blog main
indiana top stories
sanofi
bristol-myers squibb
celgene
ceo
crispr
drug prices
eli lilly
fda
gene editing
glaxosmithkline
pbms
pharmacy benefit managers
What
bio
roundup
crispr
drug
executives
pharma
advanced
alnylam’s
approval
away
bff
big
biopharma
bosley's
bosley’s
bridge
bringing
bucks
cas
ceo
ceos
conference
congress
congressional
crime
dc
deals
departure
devoted
disease
easl
editas
exit
feud
form
gathered
gene
group
groups
guiding
Language
Current search:
congress
×
national
×
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More